Felix Baker - Net Worth and Insider Trading
Felix Baker Net Worth
The estimated net worth of Felix Baker is at least $10.1 Billion dollars as of 2024-03-28. Felix Baker is the Director, 10% Owner of Seagen Inc and owns about 40,992,596 shares of Seagen Inc (SGEN) stock worth over $9.4 Billion. Felix Baker is the Director, 10% Owner of Genomic Health Inc and owns about 11,841,478 shares of Genomic Health Inc (GHDX) stock worth over $751 Million. Felix Baker is also the Director, 10% Owner of ACADIA Pharmaceuticals Inc and owns about 440,802 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $8 Million. Besides these, Felix Baker also holds Mirati Therapeutics Inc (MRTX) , BioCryst Pharmaceuticals Inc (BCRX) . Details can be seen in Felix Baker's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Felix Baker has not made any transactions after 2016-11-08 and currently still holds the listed stock(s).
Transaction Summary of Felix Baker
Felix Baker Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Felix Baker owns 31 companies in total, including IGM Biosciences Inc () , Incyte Corp () , and Kodiak Sciences Inc () among others .
Click here to see the complete history of Felix Baker’s form 4 insider trades.
Insider Ownership Summary of Felix Baker
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
IGM Biosciences Inc | 2022-03-12 | director & 10 percent owner | |
Incyte Corp | 2008-01-04 | director & 10 percent owner | |
Kodiak Sciences Inc | 2022-01-21 | director & 10 percent owner | |
Prelude Therapeutics Inc | 2022-06-17 | director & 10 percent owner | |
Kiniksa Pharmaceuticals Ltd | 2022-06-29 | director | |
Atreca Inc | 2023-10-19 | other: Former 10% Owner | |
BeiGene Ltd | 2016-02-02 | director & 10 percent owner | |
ACADIA Pharmaceuticals Inc | 2013-06-05 | 10 percent owner | |
Seagen Inc | 2020-12-31 | director & 10 percent owner | |
Alexion Pharmaceuticals Inc | 2020-05-14 | director | |
Zymeworks Inc | 2020-03-16 | director | |
Neoleukin Therapeutics Inc | 2015-08-07 | 10 percent owner | |
Aceragen Inc | 2006-03-24 | 10 percent owner | |
HOOKIPA Pharma Inc | 2019-04-17 | 10 percent owner | |
Principia Biopharma Inc | 2018-09-13 | 10 percent owner | |
Invitae Corp | 2015-08-27 | 10 percent owner | |
Bellicum Pharmaceuticals Inc | 2015-12-24 | 10 percent owner | |
Mirati Therapeutics Inc | 2013-10-24 | 10 percent owner | |
Rhythm Pharmaceuticals Inc | 2017-10-04 | 10 percent owner | |
BioCryst Pharmaceuticals Inc | 2013-08-01 | 10 percent owner | |
Intellia Therapeutics Inc | 2016-05-05 | 10 percent owner | |
XOMA Corp | 2012-03-06 | 10 percent owner | |
Ocera Therapeutics Inc | 2012-03-12 | 10 percent owner | |
Heron Therapeutics Inc | 2009-10-19 | 10 percent owner | |
XOMA Corp | 2012-03-06 | 10 percent owner | |
Talis Biomedical Corp | 2022-06-10 | director & 10 percent owner | |
DBV Technologies SA | 2022-06-13 | director & 10 percent owner | |
Spyre Therapeutics Inc | 2021-02-23 | director | |
Entrada Therapeutics Inc | 2022-05-16 | 10 percent owner | |
TScan Therapeutics Inc | 2022-05-10 | director & 10 percent owner | |
Madrigal Pharmaceuticals Inc | 2023-06-15 | director |
Felix Baker Latest Holdings Summary
Felix Baker currently owns a total of 5 stocks. Among these stocks, Felix Baker owns 40,992,596 shares of Seagen Inc (SGEN) as of November 8, 2016, with a value of $9.4 Billion and a weighting of 92.49%. Felix Baker owns 11,841,478 shares of Genomic Health Inc (GHDX) as of August 15, 2016, with a value of $751 Million and a weighting of 7.41%. Felix Baker also owns 440,802 shares of ACADIA Pharmaceuticals Inc (ACAD) as of June 5, 2013, with a value of $8 Million and a weighting of 0.08%. The other 2 stocks Mirati Therapeutics Inc (MRTX) , BioCryst Pharmaceuticals Inc (BCRX) have a combined weighting of 0.02% among all his current holdings.
Latest Holdings of Felix Baker
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
SGEN | Seagen Inc | 2016-11-08 | 40,992,596 | 228.74 | 9,376,646,409 |
GHDX | Genomic Health Inc | 2016-08-15 | 11,841,478 | 63.44 | 751,223,364 |
ACAD | ACADIA Pharmaceuticals Inc | 2013-06-05 | 440,802 | 18.20 | 8,022,596 |
MRTX | Mirati Therapeutics Inc | 2013-10-24 | 40,308 | 58.70 | 2,366,080 |
BCRX | BioCryst Pharmaceuticals Inc | 2013-08-01 | 28,361 | 5.15 | 146,059 |
Holding Weightings of Felix Baker
Felix Baker Form 4 Trading Tracker
According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in Seagen Inc (SGEN) over the past 5 years. The most-recent trade in Seagen Inc is the acquisition of 382,500 shares on November 8, 2016, which cost Felix Baker around $23 Million.
According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in Genomic Health Inc (GHDX) over the past 5 years. The most-recent trade in Genomic Health Inc is the acquisition of 100,000 shares on August 15, 2016, which cost Felix Baker around $3 Million.
According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 2,340,314 shares on June 5, 2013, which cost Felix Baker around $34 Million.
More details on Felix Baker's insider transactions can be found in the Insider Trading History of Felix Baker table.Insider Trading History of Felix Baker
- 1
Felix Baker Trading Performance
GuruFocus tracks the stock performance after each of Felix Baker's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Felix Baker is 10.96%. GuruFocus also compares Felix Baker's trading performance to market benchmark return within the same time period. The performance of stocks bought by Felix Baker within 3 months outperforms 22 times out of 37 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Felix Baker's insider trading performs compared to the benchmark.
Performance of Felix Baker
Average Relative Return
29.84%
Outperforming Transactions
62%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Relative Return(%) | 5.58 | 10.96 | 22.87 | 29.84 | 19.2 | 11.31 |
Relative Return to S&P 500(%) | 4.36 | 7.52 | 14.59 | 14.11 | 4.67 | 0.94 |
Felix Baker Ownership Network
Ownership Network List of Felix Baker
Ownership Network Relation of Felix Baker
Felix Baker Owned Company Details
What does IGM Biosciences Inc do?
Who are the key executives at IGM Biosciences Inc?
Felix Baker is the director & 10 percent owner of IGM Biosciences Inc. Other key executives at IGM Biosciences Inc include Principal Accounting Officer Steven Weber , Chief Medical Officer Chris H Takimoto , and Chief Financial Officer Misbah Tahir .
IGM Biosciences Inc () Insider Trades Summary
Over the past 18 months, Felix Baker made no insider transaction in IGM Biosciences Inc (). Other recent insider transactions involving IGM Biosciences Inc () include a net sale of 45,975 shares made by Bruce Keyt , a net sale of 11,918 shares made by George Gauthier , and a net sale of 14,987 shares made by Lisa Lynn Decker .
In summary, during the past 3 months, insiders sold 28,125 shares of IGM Biosciences Inc () in total and bought 0 shares, with a net sale of 28,125 shares. During the past 18 months, 229,745 shares of IGM Biosciences Inc () were sold and 795,616 shares were bought by its insiders, resulting in a net purchase of 565,871 shares.
IGM Biosciences Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.
IGM Biosciences Inc Insider Transactions
Felix Baker Mailing Address
Above is the net worth, insider trading, and ownership report for Felix Baker. You might contact Felix Baker via mailing address: Baker Bros. Advisors Lp, 860 Washington Street 3rd Floor, New York Ny 10014.